Rheumnow Podcast

ICYMI: Great Lectures; Great Presentations 03.07.2026 27min

Dr. Jack Cush lectures on giving a great presentation; based on 40 years of lecturing in Rheumatology.

Generic Tofacitinib (6.26.2026) 26.06.2026 30min

Dr. Jack Cush reviews the news and journal articles from RheumNow.com. Updates on tofacitinib, CAR-T therapy and AI.

DERM on RheumNow (June 2026) 26.06.2026 17min

The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects. Features Dr. Jack Cush, Editor at RheumNow.com. Show Notes:- Breckenridge Pharmaceutical received FDA approval for their generic version of tofacitinib on 6/4/26. 5 mg and 10 mg tablets are now available in the U.S. market, for both adult and pediatric use. Tofacitinib Tablets are manufactured in Martorelles, Spain. https://t.co/oAh0KQSFgs - TB Infection or reactivation is Psoriasis or Psoriatic Arthritis pts taking IL-23 inhibitors is rare, rare. Literature review showed 34 studies of IL-23i in PsO had no new TB, but 1 case of LTBI reactivation. In 8 IL-23i PsA studies there were NO new TB or LTBI reactivations https://t.co/NFIap7DSOr - BE BOLD: Bimekizumab Beats Risankizumab (LB0001) –H2H trial bimekizumab vs risankizumab in PsA for 24 weeks. At week 16; BKZ better than RZB, p=0.0058). This advantage was maintained out to week 24 (55% vs 44%; p 0.0001). - RA-BRIDGE and RA-BRANCH: FDA mandated study of the risk of venous thromboembolic events (VTE) taking baricitinib (BARI) or TNF inhibitors. The incidence rate was 0.79/100 PY for BARI combined versus 0.51/100 PY for TNFi. The hazard ratio was 1.606 (95% CI 0.969–2.660), with the upper CI exceeding the pre-specified NI margin of 1.8. Baricitinib (neither dose) was associated with a higher risk of MACE (HR 1.06), all-cause mortality (HR 0.97), arterial thromboembolism (HR 1.27), or opportunistic infections (HR 1.25). - Probiotics in Psoriatic Arthritis. (POS0290) 66 PsA patients randomized to receive either placebo or probiotic containing lactobacillus and bifidobacterium strains for 12 weeks. This trial proves no significant effect with oral probiotic supplementation in PsA. - CLE and smoking. Smoking reduces efficacy of antimalarials & worsens dz activity & damage. Advocate for smoking cessation! @Rheumnow #EULAR2026 https://t.co/pEWLJAkBAJ - Risk of Psoriasis is increased 19% by long-term exposure to Particulate Matter (PM2.5 & PM10; adjHR 1.19), while short-term exposure increases risk of psoriasis exacerbation (adjusted OR 1.03). Stronger in younger, urban, lower SES, ever-smokers, & comorbid allergies https://t.co/pd6S13RG1B

Do You Zoster Vaccinate? (6.19.2026) 19.06.2026 29min

Dr. Jack Cush reviews the news, journal reports and best ways to review EULAR 2026.

RheumNow EULAR 2026 Rheumatology Round Up 12.06.2026 56min

Drs. Jack Cush & Arthur Kavanaugh, two of rheumatology’s most trusted voices, provide a breakdown of the latest breakthroughs and hottest topics in rheumatology from the EULAR 2026 meeting in London.

EULAR 2026 RA Topic Panel 11.06.2026 54min

Join Drs. Bella Mehta, Jack Cush, Janet Pope, and Jon Kay for a focused conversation on the latest in rheumatoid arthritis care from emerging data and treatment strategies to real-world challenges in diagnosis and management. Hear expert perspectives, clinical pearls, and what’s shaping RA practice right now.

CAR-T Topic Panel EULAR 2026 10.06.2026 38min

Join Drs. Jack Cush, Alfred Kim, Janet Pope, and Yuz Yusof for a focused conversation on the latest in CAR-T from emerging data and treatment strategies to real-world challenges in diagnosis and management. Hear expert perspectives, clinical pearls, and what's shaping CAR-T practice right now.

EULAR 2026 PsA Update What's Changing in Psoriatic Arthritis Care? 09.06.2026 48min

Join Drs. Jack Cush, Peter Nash, Antoni Chan, and Nelly Ziade for an expert discussion on the most important psoriatic arthritis developments emerging from EULAR 2026. This focused conversation explores new clinical data, evolving treatment strategies, and practical approaches to managing PsA in everyday practice. From advances in biologic and targeted therapies to ongoing challenges in diagnosis, disease monitoring, and patient care, the panel shares key insights and take-home messages that every rheumatology clinician should know. Tune in for expert perspectives, clinical pearls, and a comprehensive look at what's shaping the future of psoriatic arthritis management.

RA Topic Podcast compilation 08.06.2026 1h 34min

2026 EULAR PreviewBeyond BMI: Altered Body Composition in Rheumatoid ArthritisCAR-T For Rheumatoid ArthritisThis Is a Woman’s World: Women's Health in Rheumatic DiseaseLow dose Blinatumomab: Many Relapse with an Unexpected SurpriseDoctor's Orders or Patient's Choice: BACH study findingsAnother Way to Leverage NK Cells to Kill B Cells, This Time Without CARsDigital Patient Education in RAMaking Methotrexate More EffectiveAre we failing in the treatment of RA-ILD?Using AI to Predict Progression to RATreat to Target Works in Elderly Onset RARA BRIDGE and RA BRANCH trials: Baricitinib and VTE RiskImproving Referrals for Inflammatory ArthritisCombination Therapy: Off the Shelf Allogenic NK and Rituximab in Rheumatic Disease

PsA Topic Podcast compilation 08.06.2026 1h 36min

2026 EULAR PreviewImaging in Subclinical Psoriatic ArthritisDietary Interventions in PsAThis Is a Woman’s World: Women's Health in Rheumatic DiseaseImpact of Synovial Biopsy-Driven Therapeutic Stratification in PsACan We Stop PsA Before it Starts?BE BOLD: Going Where No PsA Trial Has Gone BeforeBMI Outranks Treatment in PsA Outcomes?Debate: Combination Therapies for Inflammatory Arthritis?Combination Biologics in PsA: MRI Findings from AFFINITYCombination Therapy in SpAThe Case for Dual Pathway Blockade in Refractory PsAThe AFFINITY Study: Combination Treatment in PsAPsA Potpourri: Probiotics & Head-to-Head DataTransition from Psoriasis to Psoriatic ArthritisMACE and Safety Profile of bDMARDs/JAKis in axSpA and PsAGuselkumab Delivers Across the PsA Disease Spectrum: APEX Trial

CAR T Topic compilation 08.06.2026 31min

2026 EULAR PreviewCAR-T For Rheumatoid ArthritisWhat Happens when CAR-T Fails Managing Disease RecurrenceManagement of Relapses After CAR-T Therapy in SLE, SSc and IIMHow Many CAR-Ts Do We Need to Test Drive?

EULAR 2026 Daily Podcast Day 4c 08.06.2026 24min

Guselkumab Delivers Across the PsA Disease Spectrum: APEX TrialRA BRIDGE and RA BRANCH trials: Baricitinib and VTE RiskImproving Referrals for Inflammatory Arthritis"Combination Therapy: Off the Shelf Allogenic NK and Rituximab in Rheumatic Disease

EULAR 2026 Daily Podcast Day 4b 06.06.2026 20min

Are we failing in the treatment of RA-ILD?Using AI to Predict Progression to RATreat to Target Works in Elderly Onset RA

EULAR 2026 Daily Podcast Day 4a 06.06.2026 32min

MACE and Safety Profile of bDMARDs/JAKis in axSpA and PsAHow Many CAR-Ts Do We Need to Test Drive?Making Methotrexate More Effective

Day 4 Recap EULAR 2026 06.06.2026 39min

Join Drs. Jack Cush, Mrinalini Dey, Antoni Chan, and Yuz Yusof for a lively discussion of the top presentations, breakthrough science, and clinical pearls from Day 4 of the EULAR 2026 Congress. Abstracts discussed included: LB001LB002LB003LB005LB007LB009RA PlenaryPOS1350

EULAR 2026 Daily Podcast Day 3a 05.06.2026 33min

Debate: Combination Therapies for Inflammatory Arthritis?Combination Biologics in PsA: MRI Findings from AFFINITYCombination Therapy in SpADigital Patient Education in RAThe Case for Dual Pathway Blockade in Refractory PsAThe AFFINITY Study: Combination Treatment in PsAPsA Potpourri: Probiotics & Head-to-Head DataTransition from Psoriasis to Psoriatic Arthritis

Day 3 Recap EULAR 2026 05.06.2026 47min

Join Drs. Jack Cush, Jiha Lee, Nelly Ziade, and Sheila Reyes for a lively discussion of the top presentations, breakthrough science, and clinical pearls from Days 3 of the EULAR 2026 Congress. Abstracts discussed included:OP0348 POS0290 OP0342 POS1068 POS0201 POS0288

EULAR 2026 Daily Podcast Day 2c 05.06.2026 32min

BE BOLD: Going Where No PsA Trial Has Gone BeforeBMI Outranks Treatment in PsA Outcomes?What Happens when CAR-T Fails Managing Disease RecurrenceManagement of Relapses After CAR-T Therapy in SLE, SSc and IIMDoctor's Orders or Patient's Choice: BACH study findingsAnother Way to Leverage NK Cells to Kill B Cells, This Time Without CARs

EULAR 2026 Daily Podcast Day 2b 04.06.2026 18min

Low dose Blinatumomab: Many Relapse with an Unexpected SurpriseCan We Stop PsA Before it Starts?Impact of Synovial Biopsy-Driven Therapeutic Stratification in PsA

Daily Recap Day 1 + 2 EULAR 2026 04.06.2026 36min

Join Dr. Jack Cush and RheumNow.com faculty for a lively discussion of the top presentations, breakthrough science, and clinical pearls from Days 1 & 2 of the EULAR 2026 Congress. Abstracts discussed included: OP0177OP0244 OP001OP008OP0205 OP018OP0204POS0788